---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039871"
form_type: "8-K"
ticker: "OFIX"
cik: "0000884624"
company_name: "Orthofix Medical Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T03:25:47.437541+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Orthofix Q2 2023 revenue $187M (+7% pro forma), raises FY adjusted EBITDA guidance

## Summary
- Net sales $187.0M, up 58% reported / 7% pro forma constant currency YoY.
- GAAP EPS $(1.07); adjusted EPS $0.02; adjusted EBITDA $9.9M (5.3% margin).
- Bone Growth Therapies grew 10.3% YoY; U.S. spine implants +7% pro forma.
- FY23 net sales guidance raised to $752-758M; adjusted EBITDA to $42-46M.
- Full commercial launch of WaveForm A interbody and TrueLok Phantom/Tornado hinges.

## SEC filing metadata
- accession: 0000950170-23-039871
- form_type: 8-K
- ticker: OFIX
- cik: 0000884624
- company_name: Orthofix Medical Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/884624/000095017023039871/0000950170-23-039871-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/884624/000095017023039871/ofix-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039871
- JSON: https://secwatch.observer/filing/0000950170-23-039871.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039871.txt

## Key facts
- Earnings Releases
  Orthofix Medical Inc. reported the quarter ended June 30, 2023 results: revenue $187.0 million, EPS $(1.07). Guidance raised.
  - Period: the quarter ended June 30, 2023
  - Revenue: $187.0 million
  - EPS: $(1.07)
  - Guidance: raised
  - Result: reported results
  source text: Legal judgments/sett --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Orthofix Reports Second Quarter 2023 Results and Raises Revenue and Adjusted EBITDA Guidance • Net sales of $187.0 million, an increase of 58% on a reported basis and 7% on a pro forma constant currency basis over prior year • Bone Growth Therapies growth of 10%, marking two consecutive quarters with
  evidence_url: https://www.sec.gov/Archives/edgar/data/884624/000095017023039871/0000950170-23-039871-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.